Abstract
Forty-one previously untreated patients with limited-stage small cell lung cancer (SCLC) entered a combined-modality study. Patients were initially treated with etoposide and cisplatin and concurrent chest radiotherapy. Patients then received two more cycles of etoposide/cisplatin followed by four cycles of individualized chemotherapy based on in vitro drug sensitivity testing if available, or a standard regimen of vincristine/doxorubicin/cyclophosphamide. Forty patients have completed therapy and are evaluable for response. Twenty-nine (73%) had a complete response and the remaining 11 (27%) achieved partial response. The median potential follow-up is now 3 years (range 4 months to 5 years). The median projected actuarial survival is 27 months with an actuarial survival of >90% at 1 year and 65% at 2 years. Four of 41 patients (10%) have died from treatment toxicity, including three who died of combined-modality pneumonitis and one of neutropenic sepsis. The median projected actuarial survival is nearly twice as long as in our previous combined-modality treatment regimens for limited-stage small cell lung cancer.
Original language | English (US) |
---|---|
Pages (from-to) | S21-S26 |
Journal | Lung Cancer |
Volume | 9 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - Aug 1993 |
Keywords
- Concurrent
- Hyperfractionation
- Small cell lung cancer
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research